These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17018301)

  • 1. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Pedersen M
    J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808
    [No Abstract]   [Full Text] [Related]  

  • 6. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
    [No Abstract]   [Full Text] [Related]  

  • 7. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD.
    Jamboti J
    Nephrology (Carlton); 2007 Jun; 12(3):316. PubMed ID: 17498132
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
    Khurana A; Greene JF; High WA
    J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA; Rodby RA
    Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
    Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM; Port M; Medina C; Lancelot E; Fayoux E; Ballet S; Corot C
    Toxicology; 2008 Jun; 248(2-3):77-88. PubMed ID: 18440117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.